^
CANCER:

Acute Myelogenous Leukemia





Show legend
Group by Gene:
Include preclinical:

0
Bcl2 inhibitor
venetoclax
venetoclax
gilteritinib
1
Multi-tyrosine kinase inhibitor
midostaurin
ponatinib
cabozantinib tablet
2
DNA methylation inhibitor
azacitidine
cytarabine
3
DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + clofarabine
cytarabine + fludarabine IV
cytarabine
4
DNMT inhibitor
decitabine
azacitidine oral
IDH1 inhibitor
5
IDH1 inhibitor
ivosidenib
olutasidenib
GSK321
cytarabine + etoposide IV
6
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + etoposide IV + mitoxantrone
cytarabine + doxorubicin hydrochloride
FLT3 inhibitor
quizartinib
HEC73543
FF-10101
7
FLT3 inhibitor
XY0206
STI-8591
D-65476
BGS-2456
AIU2008
FLT3 inhibitor
clofarabine
8
DNA synthesis inhibitor
asparagine cytarabine conjugate
temozolomide
9
Topoisomerase II inhibitor, DNA cross linking agent
idarubicin hydrochloride
10
DNMT inhibitor, Cytidine deaminase inhibitor
decitabine / cedazuridine
KO-539
11
Menin-MLL inhibitor
SNDX-5613
VTP-50469
DS-1594
12
SYK inhibitor
GS-9973
GS-9876
13
PLK4 inhibitor
CFI-400945
14
pan-RAF inhibitor
LY3009120
RG6185
MGD006
15
CD3 agonist, CD123 inhibitor
XmAb14045
MGD024
IDH2 inhibitor
16
IDH2 inhibitor
enasidenib
TQB3455
17
c-MET inhibitor
LY2801653
18
AXL inhibitor
BGB324
TP-0903
19
Purinergic receptor P1 agonist, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + cladribine
cytarabine + cladribine
20
ILT-3 inhibitor
IO-202
21
CD47 inhibitor
GS-4721
22
Purinergic receptor P1 agonist, DNMT inhibitor
decitabine + cladribine
23
Apoptosis stimulant
arsenic trioxide
pelareorep
24
Immunostimulant
DCP-001
25
NMT inhibitor
PCLX-001
26
DNA topoisomerase inhibitor
L-ANN
27
E-selectin antagonist
APL-106
28
Alkylating agent, DNA synthesis inhibitor
fludarabine IV + treosulfan
29
S1P receptor agonist
KRP-203
30
PDH inhibitor, α-KGDH inhibitor
devimistat
31
NK cell stimulant
CYNK-001
32
PD1 inhibitor
PD1 inhibitor
nivolumab
33
Bcr-abl tyrosine kinase inhibitor
nilotinib
34
MDM2 inhibitor, FLT3 inhibitor
quizartinib + RAIN-32
35
LSD1 inhibitor
ORY-1001
CPI-482
36
CDK19 inhibitor, CDK8 inhibitor
RVU120
37
CDK4 inhibitor, CDK6 inhibitor
palbociclib
abemaciclib
38
MDM2 inhibitor
RG7388
HDM201
39
WEE1 inhibitor
AZD1775
40
NEDD8 activating enzyme inhibitor, Bcl2 inhibitor
MLN4924 + ABBV-167
venetoclax + MLN4924
41
p53 reactivator
APR-246
42
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
43
CTLA4 inhibitor
ipilimumab
44
DNA synthesis inhibitor, DNA-directed DNAP inhibitor, Multi-tyrosine kinase inhibitor
cytarabine + midostaurin
45
Bcl-xL inhibitor
A-1331852
46
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
bosutinib
47
Bcl2 inhibitor, CD47 inhibitor
venetoclax + GS-4721
48
TIM-3 antagonist
MBG453
49
Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
ABT 263
50
ALK inhibitor
crizotinib
51
Bcl2 inhibitor, FLT3 inhibitor
venetoclax + quizartinib
52
NEDD8 activating enzyme inhibitor, HDAC inhibitor
MLN4924 + belinostat
53
PARP inhibitor
talazoparib
olaparib
54
RARα agonist
tamibarotene
55
XPO1 inhibitor
selinexor
bortezomib
56
Proteasome inhibitor
carfilzomib
ixazomib
57
Topoisomerase II inhibitor, RNA synthesis inhibitor
dactinomycin
58
Topoisomerase II inhibitor, DNMT inhibitor
etoposide IV + decitabine
59
c-KIT-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor
MGTA-117
60
CD52 inhibitor, CD123-targeted CAR-T immunotherapy
alemtuzumab + UCART123
61
CD123-targeted CAR-T immunotherapy
UCART123
ACLX-002
62
Bcl2 inhibitor, Hypomethylating agent
Hypomethylating agent + venetoclax
gemtuzumab ozogamicin
63
CD33-targeted antibody-drug conjugate, DNA replication inhibitor
IMGN779
SGN-CD33A
HAG + azacitidine
64
DNA methylation inhibitor, Chemotherapy
HIA + azacitidine
HDA + azacitidine
65
Multi-tyrosine kinase inhibitor, FLT3 inhibitor
FLT3 inhibitor + gilteritinib
gilteritinib + quizartinib
66
Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor
cytarabine / daunorubicin liposomal formulation
7+3 (DAC)
DCAG
HIA
CDIAG
IA
67
Chemotherapy
CLAG
FLAG-IDA
DAV
FLAI
DA
ADE
68
MEK inhibitor, FLT3 inhibitor
MEK inhibitor + FLT3 inhibitor
69
LIMK2 inhibitor, FLT3 inhibitor
FLT3 inhibitor + LIMK2 inhibitor
70
mTOR inhibitor
mTOR inhibitor
PI3K inhibitor
71
PI3K inhibitor
GDC-0941
BAY 1082439
72
BET inhibitor, FLT3 inhibitor
FLT3 inhibitor + BET inhibitor
73
HDAC inhibitor
HDAC inhibitor
74
Tyrosine kinase inhibitor, Bcl2 inhibitor
Bcl2 inhibitor + Tyrosine kinase inhibitor
75
CD19-targeted CAR-T immunotherapy
CD19-targeted CAR-T immunotherapy
76
T-lymphocyte cell therapy
T-lymphocyte cell therapy
77
DHODH inhibitor
DHODH inhibitor
78
Josephin inhibitor
Josephin inhibitor
79
CD64-targeted CAR-T immunotherapy
CD64-targeted CAR-T immunotherapy
cytarabine + idarubicin hydrochloride
80
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
cytarabine + idarubicin hydrochloride + fludarabine IV
cytarabine + idarubicin hydrochloride
sorafenib
81
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + gilteritinib
sorafenib + LY3009120
sorafenib
82
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, Multi-tyrosine kinase inhibitor, DNA intercalator
cytarabine + midostaurin + daunorubicin
83
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, DNA intercalator
cytarabine + daunorubicin
cytarabine + daunorubicin + mitoxantrone
84
Topoisomerase II inhibitor, Purinergic receptor P1 agonist, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor
cytarabine + idarubicin hydrochloride + cladribine
85
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA cross linking agent
clofarabine + idarubicin hydrochloride
86
SMO protein inhibitor, Hedgehog cell-signalling pathway inhibitor
glasdegib
87
Topoisomerase II inhibitor, Purinergic receptor P1 agonist, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + mitoxantrone + cladribine
88
IDH1 inhibitor, Bcl2 inhibitor
venetoclax + ivosidenib
89
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
90
PDGFR β inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002
venetoclax + gilteritinib
91
Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + midostaurin
venetoclax + ponatinib
92
DNA methylation inhibitor, Bcl2 inhibitor
venetoclax + azacitidine
93
MDM2 inhibitor, Bcl2 inhibitor
venetoclax + RG7388
94
JAK1 inhibitor, JAK2 inhibitor, Bcl2 inhibitor
venetoclax + ruxolitinib
95
Myeloid kinome inhibitor, SYK inhibitor, FLT3 inhibitor
HM43239
96
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
97
IDH2 inhibitor, Bcl2 inhibitor
venetoclax + enasidenib
98
CDK4 inhibitor, CDK6 inhibitor, Bcl2 inhibitor
venetoclax + palbociclib
99
DNMT inhibitor, DNA synthesis inhibitor
decitabine + clofarabine
100
IRAK-4 inhibitor, FLT3 inhibitor
CA-4948
HPB-092
101
PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
imatinib
102
DNMT inhibitor, Cytidine deaminase inhibitor, Bcl2 inhibitor
venetoclax + decitabine / cedazuridine
103
CD33-targeted antibody-drug conjugate, DNA replication inhibitor, Multi-tyrosine kinase inhibitor
midostaurin + gemtuzumab ozogamicin
104
BET inhibitor, Bcl2 inhibitor
venetoclax + ABBV 075
venetoclax + ABBV-744
105
Chk2 inhibitor, FLT3 inhibitor
PHI-101
106
TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
lenalidomide
venetoclax + SNDX-5613
107
Menin-MLL inhibitor, Bcl2 inhibitor
venetoclax + DS-1594
venetoclax + KO-539
108
TRAIL R2 agonist, Bcl2 inhibitor, TRAIL R1 agonist
venetoclax + ABBV-621
109
CD33-targeted antibody- radioimmunoconjugate, α radiation emission
lintuzumab-Ac225
110
CSF-1R inhibitor, c-KIT inhibitor, FLT3 inhibitor, AKT inhibitor, FMS kinase inhibitor
pexidartinib
111
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, Bcl2 inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
venetoclax + chidamide
112
CD123-targeted antibody-drug conjugate, DNA replication inhibitor
IMGN632
SGN-CD123A
113
PIM inhibitor, FLT3 inhibitor
MEN1703
quizartinib + AZD1208
114
Lymphoid kinome inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
CG-806
115
BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
OTX015
116
CD123-targeted antibody-drug conjugate, DNA replication inhibitor, Bcl2 inhibitor
venetoclax + IMGN632
117
IDH2 inhibitor, DNMT inhibitor, Cytidine deaminase inhibitor, Bcl2 inhibitor
venetoclax + enasidenib + decitabine / cedazuridine
118
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + sorafenib
119
pan-RAF inhibitor, PDGFR β inhibitor, PDGFR α inhibitor, Multi-tyrosine kinase inhibitor, FLT3 inhibitor
sorafenib + ARO-002
120
STAMP inhibitor, Bcr-abl tyrosine kinase inhibitor
asciminib
121
Chk1 inhibitor, Chk2 inhibitor
ACR-368
122
Retinoic acid receptor agonist, Telomerase inhibitor, Cytotoxic T lymphocyte stimulant, Apoptosis stimulant
tretinoin + arsenic trioxide
123
Elongation factor 2 inhibitor, IL-3 antagonist, CD123 inhibitor
tagraxofusp-erzs
124
CD45-targeted antibody- radioimmunoconjugate conjugate, α radiation emission
I-131-apamistamab
125
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, Bcl2 inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
venetoclax + dasatinib
126
Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor, Bcl2 inhibitor
paclitaxel + cytarabine + idarubicin hydrochloride
127
CD33-targeted antibody-drug conjugate, DNA replication inhibitor, PARP inhibitor
talazoparib + gemtuzumab ozogamicin
128
STAT5 inhibitor, JAK2 inhibitor, FLT3 inhibitor
CEP-701
129
Topoisomerase II inhibitor, DNMT inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + decitabine + mitoxantrone
130
Topoisomerase II inhibitor, DNA synthesis inhibitor, DNA cross linking agent, DNA-directed DNAP inhibitor, Apoptosis stimulant, Ribonucleotide reductase inhibitor
cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea
131
VEGFR inhibitor, PDGFR inhibitor, BRD3 inhibitor, BRD4 inhibitor, c-KIT inhibitor, Bcl2 inhibitor, BRD2 inhibitor
venetoclax + sunitinib + I-BET151
132
MCL1 inhibitor, Protein synthesis inhibitor, Proteasome inhibitor, DNA synthesis inhibitor, MYC inhibitor, DNA-directed DNAP inhibitor, Apoptosis stimulant, G1-S-specific cyclin-D1 inhibitor
cytarabine + bortezomib + omacetaxine mepesuccinate
133
CDK9 inhibitor, Casein kinase 1 alpha inhibitor, p53 stimulant, CDK7 inhibitor
BTX-A51
134
Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor, Multi-tyrosine kinase inhibitor
midostaurin + cytarabine / daunorubicin liposomal formulation
135
RARα agonist, DNA methylation inhibitor
azacitidine + tamibarotene
136
CD33-targeted antibody- radioimmunoconjugate, α radiation emission, Bcl2 inhibitor
venetoclax + lintuzumab-Ac225
137
p53 reactivator, Bcl2 inhibitor
venetoclax + APR-246
138
Elongation factor 2 inhibitor, IL-3 antagonist, CD123 inhibitor, Bcl2 inhibitor
venetoclax + tagraxofusp-erzs
139
PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
avapritinib
140
TNFα inhibitor, IL-12 inhibitor, DNA methylation inhibitor, IL-6 inhibitor
lenalidomide + azacitidine
141
HDAC inhibitor, DNMT inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine + decitabine + vorinostat
142
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
143
CD30-targeted antibody-drug conjugate, Microtubule inhibitor
brentuximab vedotin
144
PDGFR β inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor, DNA synthesis inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002 + cytarabine / daunorubicin liposomal formulation
145
CBP inhibitor, EP300 inhibitor
CCS1477
146
MERTK inhibitor, AXL inhibitor, Bcl2 inhibitor
venetoclax + ONO-7475
147
MCL1 inhibitor, Bcl2 inhibitor
venetoclax + AZD5991
venetoclax + AMG 176
148
DNMT inhibitor, Bcl2 inhibitor, FLT3 inhibitor
FLT3 inhibitor + venetoclax + decitabine
149
Bcl2 inhibitor, PARP inhibitor
venetoclax + olaparib
150
Topoisomerase II inhibitor, DNA intercalator
daunorubicin
doxorubicin hydrochloride
151
Topoisomerase II inhibitor
mitoxantrone
etoposide IV
152
MCL1 inhibitor
AZD5991
S63845
153
HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
chidamide
154
DNA PK inhibitor
M3814
155
Autophagy inhibitor, FLT3 inhibitor
quizartinib + Lys05
156
Telomerase inhibitor
BIBR1532
157
CD33-targeted antibody-drug conjugate, DNA replication inhibitor, FLT3 inhibitor
quizartinib + IMGN779
selumetinib
trametinib
158
MEK inhibitor
CI-1040
PD-0325901
PD98059
159
B7-H3-targeted CAR-T immunotherapy
s
160
BMI1 inhibitor, MEK inhibitor
trametinib + BMIi-1
161
MCL1 inhibitor, BMI1 inhibitor
S63845 + BMIi-1
162
PP2A inhibitor
DT-061
163
Aurora kinase A inhibitor
MLN8237
164
Hedgehog cell-signalling pathway inhibitor
GANT61
165
MELK inhibitor
OTS167
166
Bcr-abl tyrosine kinase inhibitor, Bcl2 inhibitor
olverembatinib + APG-2575
167
CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor
DSP-2033
168
LSD1 inhibitor, Bcl2 inhibitor
venetoclax + INCB59872
venetoclax + MK-3543
169
Annexin A1 inhibitor
MDX-124
170
MCL1 inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + AMG 176
171
JAK1 inhibitor, JAK2 inhibitor, LSD1 inhibitor
LSD1 inhibitor + ruxolitinib
172
FLT3 inhibitor, ERN1 inhibitor
quizartinib + STF-083010
173
ERN1 inhibitor
STF-083010
174
PI3K inhibitor, mTOR inhibitor, FLT3 inhibitor
quizartinib + PF-04691502
175
FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
TKI258
176
CXCR4 antagonist, E-selectin inhibitor, FLT3 inhibitor
quizartinib + GMI-1359
177
PIM inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + AZD1208
178
CDK4 inhibitor, Menin-MLL inhibitor, CDK6 inhibitor
abemaciclib + KO-539
179
BRD3 inhibitor, BRD4 inhibitor, Menin-MLL inhibitor, BRD2 inhibitor
KO-539 + OTX015
180
Ubiquitin pathway modulator, FLT3 inhibitor, GSPT1 degrader
quizartinib + CC-90009
181
pan-CLK inhibitor
CTX-712
SM09419
182
JAK1 inhibitor, JAK2 inhibitor
ruxolitinib
183
Microtubule inhibitor, CD74-targeted antibody-drug conjugate
STRO-001
184
KIF11 inhibitor, Multi-tyrosine kinase inhibitor
ponatinib + SB-715992
cabozantinib tablet + SB-715992
185
MYC inhibitor
WB100
GT19077
186
p53 stimulant
thioureidobutyronitrile
187
pan-RAF inhibitor, DDR inhibitor
PHI-501
188
Mitochondrial OXHPHOS inhibitor, mTOR inhibitor
ME-344
189
Folate receptor 1-targeted small molecule-drug conjugate, Topoisomerase I inhibitor
ELU001
190
PTPN11 inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + ERAS-601
gilteritinib + SHP099
191
CDK9 inhibitor, FLT3 inhibitor
CDDD11-8
192
PIM inhibitor, STAT5 inhibitor, RPS6 inhibitor, STAT3 inhibitor, IKKe inhibitor, NF-κB inhibitor, mTOR inhibitor, JAK2 inhibitor, SYK inhibitor, FLT3 inhibitor, AKT inhibitor
EC-70124
193
5T4-targeted CAR-T immunotherapy
OXB302
194
RAC1 inhibitor
NSC23766
195
ACVR1 inhibitor, TGF-β RI antagonist
TP-0184
196
β-catenin inhibitor, Wnt signalling pathway inhibitor, Bcl2 inhibitor
venetoclax + BC2059
197
β-catenin inhibitor, BRD3 inhibitor, BRD4 inhibitor, Wnt signalling pathway inhibitor, BRD2 inhibitor
OTX015 + BC2059
198
USP47 inhibitor, USP7 inhibitor
P22077
199
PRMT5 inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + PRT811
200
DHODH inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + DUP 785
201
CDK inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + MK-7965
202
TCR modulator, Minor histocompatibility antigen 1 modulator
BSB-1001
203
RET inhibitor, FLT3 inhibitor
PLD-102
204
CD39 inhibitor, CD73 inhibitor
INT-1B3
205
Menin-MLL inhibitor, MEK inhibitor
selumetinib + SNDX-5613
206
MERTK inhibitor
RGX-019
207
FLT3-targeted antibody-drug conjugate, Multi-tyrosine kinase inhibitor
midostaurin + 20D9-ADC
208
c-KIT-targeted antibody-drug conjugate, Microtubule inhibitor
NN3201
LOP628
209
MERTK-targeted antibody-drug conjugate, Microtubule inhibitor
RGX-019-MMAE
210
CD123-targeted antibody-drug conjugate, DNA replication inhibitor, FLT3 inhibitor
quizartinib + SGN-CD123A
211
SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
MEDI7247
212
CDC7 kinase inhibitor
SGR-2921
213
CD123-targeted antibody-drug conjugate
BYON4413
214
pan-RAF inhibitor, MEK1 inhibitor
cobimetinib + RG6185
215
CDK19 inhibitor, Multi-tyrosine kinase inhibitor, CDK8 inhibitor
gilteritinib + RVU120
216
Bcl-xL degrader
DT2216
217
DNMT inhibitor, Bcl2 inhibitor
venetoclax + NTX-301
218
SMARCA4 inhibitor, SMARCA2 inhibitor
FHD-286
219
Menin-MLL inhibitor, SMARCA4 inhibitor, SMARCA2 inhibitor
SNDX-5613 + FHD-286
220
BRD3 inhibitor, BRD4 inhibitor, SMARCA4 inhibitor, SMARCA2 inhibitor, BRD2 inhibitor
OTX015 + FHD-286
221
MLL1 inhibitor, Bcl2 inhibitor
venetoclax + JNJ-6617
222
XPO1 inhibitor, Menin-MLL inhibitor
selinexor + KO-539
223
CK1α degrader
PIN-A1
224
CK1α degrader, Multi-tyrosine kinase inhibitor
gilteritinib + PIN-A1
225
RAS inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + RMC-7977
ABBV-744
226
BET inhibitor
CPI-0610
JQ-1
227
pan-CLK inhibitor, Bcl2 inhibitor
venetoclax + SM09419
228
Electron transport complex I inhibitor, Bcl2 inhibitor
venetoclax + IACS-010759
229
AXL inhibitor, FLT3 inhibitor
JRF104
230
pan-CLK inhibitor, Multi-tyrosine kinase inhibitor
midostaurin + SM09419
231
PD-L1 inhibitor
avelumab
232
Menin-MLL inhibitor, Multi-tyrosine kinase inhibitor
ponatinib + MI-503
gilteritinib + MI-503
233
FGFR2 inhibitor, FGFR1 inhibitor, JAK inhibitor, PDGFR inhibitor, HPK1 inhibitor, FLT3 inhibitor
Max-40279
234
CD123-targeted antibody-drug conjugate, KIF11 inhibitor
VIP943
235
Proteasome inhibitor, Reactive oxygen species stimulant, Photosensitizer
bortezomib + verteporfin
236
HDAC inhibitor, DNA synthesis inhibitor, DNA-directed DNAP inhibitor, DNA methylation inhibitor
cytarabine + azacitidine + panobinostat
237
CXCR4 antagonist, pan-RAF inhibitor, E-selectin inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + GMI-1359
238
CD70-targeted CAR-T immunotherapy
ALLO-316
239
DOT1L inhibitor
EPZ-5676
240
Thymidylate synthase inhibitor
5-fluorouracil
241
Electron transport complex I inhibitor, FLT3 inhibitor
quizartinib + IACS-010759
242
Bcr-abl tyrosine kinase inhibitor, MDM2 inhibitor
olverembatinib + APG-115
243
CD33-targeted antibody-drug conjugate, CD7-targeted antibody-drug conjugate, Microtubule inhibitor
BVX001
244
SYK inhibitor, FLT3 inhibitor
CB-659
245
IDH2 inhibitor, IDH1 inhibitor, Multi-tyrosine kinase inhibitor, Bcl2 inhibitor
venetoclax + midostaurin + LY3410738
246
HSP90 inhibitor
LAM 003
247
PDGFR β inhibitor, PDGFR α inhibitor, USP10 inhibitor, FLT3 inhibitor
ARO-002 + Wu-5
248
Bcl2 inhibitor, CD70 inhibitor
venetoclax + ARGX-110
249
Electron transport complex I inhibitor
IACS-010759
250
PDGFR β inhibitor, Menin-MLL inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002 + MI-503
251
Menin-MLL inhibitor, FLT3 inhibitor
quizartinib + MI-503
252
Mesothelin-targeted antibody-drug conjugate, Microtubule inhibitor
BAY 94-9343
253
HDAC inhibitor, PI3K inhibitor, Multi-tyrosine kinase inhibitor
gilteritinib + CUDC-907
254
BET inhibitor, BRD4 inhibitor, MYC inhibitor, FLT3 inhibitor
quizartinib + PLX51107
255
BET inhibitor, BRD4 inhibitor, MYC inhibitor
PLX51107
256
ACVR1 inhibitor, Bcl2 inhibitor, TGF-β RI antagonist
venetoclax + TP-0184
257
Menin-MLL inhibitor, LSD1 inhibitor
SNDX-5613 + ORY-1001
258
CXCR4 antagonist, FLT3 inhibitor
quizartinib + LY2510924
259
Nucleophosmin inhibitor
NSC348884
260
Tyrosine kinase inhibitor, PDGFR α inhibitor, c-KIT inhibitor, FLT3 inhibitor
AG-1296
261
PDGFR inhibitor, c-KIT inhibitor, FLT3 inhibitor
MLN518
262
VEGFR-2 inhibitor, c-KIT inhibitor, FLT3 inhibitor
SU5614
263
Hepatocyte growth factor inhibitor, Trk inhibitor, TrkA receptor antagonist, PKC inhibitor
K-252a
264
STAT3 inhibitor, Insulin receptor substrate protein inhibitor, IGF-1R inhibitor
ASP7487 + NT-157
265
HSP90 inhibitor, Bcl2 inhibitor
venetoclax + LAM 003
266
WDR5 inhibitor
OICR-9429
267
SF3B1 inhibitor
E7107
268
HDAC inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor, CSF-1R inhibitor, JAK2 inhibitor, FLT3 inhibitor
SB939 + pacritinib
269
Topoisomerase II inhibitor, Phospholipase A2 inhibitor, DNA cross linking agent, PDE3 inhibitor
idarubicin hydrochloride + anagrelide
No biomarker
FLT3 mutation
FLT3-TKD mutation
FLT3-ITD mutation
FLT3-ITD mutation + FLT3-TKD mutation
FLT3‐ITD
FLT3 D835Y
FLT3 F691L
FLT3 G846S
FLT3 wild-type
FLT3 D835
FLT3 D835H
FLT3 I836
FLT3 positive
FLT3-ITD mutation + FLT3 D835
FLT3 expression
FLT3 V592_D593INSDFREY
FLT3 Y591_V592INSVDFREYE
FLT3 E588_Y589INSKYFYVDFRE
FLT3 D835G
FLT3 D835A
FLT3 Y842C
FLT3 G619C
FLT3 D651G
FLT3 I687F
FLT3 NPOS + FLT3 D835N
FLT3 840GS
FLT3 N676K
FLT3-ITD expression
FLT3 D835E
FLT3-ITD mutation + FLT3 F691L
FLT3-ITD mutation + FLT3 D835Y
FLT3 D835N
FLT3 D835V
FLT3 D698N
FLT3 overexpression
FLT3 N676T
FLT3 N676D + FLT3 Y842C
FLT3 N676D
FLT3 mutation + MLL mutation
FLT3 D839G
FLT3 F691L + FLT3 Y842C
FLT3 F691L + FLT3 D839G
FLT3 F691L + FLT3 D835H
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L
FLT3 F691L + FLT3 D835F
FLT3 F691L + FLT3 D835Y
FLT3 F691L + FLT3 D835V
FLT3 Y842H
FLT3 A627T
FLT3 D835F
FLT3-ITD mutation + MLL rearrangement
MLL rearrangement + FLT3 mutation
FLT3 G697R
FLT3 V592A + FLT3 D835N
IDH1 mutation
IDH1 R132H
IDH1 R132C
IDH1 R132L
IDH1 R132
IDH1 R132S
IDH1 R132G
IDH1 R132C + IDH1 S280F
TP53 mutation
TP53 mutation + Chr del(17p)
TP53 wild-type
TP53 R248Q
RUNX1-RUNX1T1 fusion
NPM1 mutation
NPM1 exon 11 mutation
NPM1 W288
NPM1 expression
IDH2 mutation
IDH2 R172K
IDH2 R140Q
IDH2 R140
IDH2 R172
FLT3‐ITD  + NPM1 mutation
NPM1 mutation + FLT3-TKD mutation
FLT3 mutation + NPM1 mutation
FLT3-ITD mutation + NPM1 mutation
FLT3-ITD F692L + NPM1 mutation
SRSF2 mutation
CD123 positive
CD123 overexpression
SRSF2 P95L
SRSF2 P95H
CD123 expression
PML-RARA fusion
FLT3‐ITD + WT1 mutation
FLT3‐ITD + DNMT3A mutation
DNMT3A mutation
CD33 positive
CD33 expression
DNMT3A R882
KIT mutation
FLT3 mutation + DNMT3A mutation
Chr t(8;21) + KIT mutation
FLT3-ITD mutation + WT1 mutation
KIT D816V
KIT positive
DNMT3A R882H
PML-RARA T285I
DNMT3A mutation + FLT3-ITD mutation
KIT N822K
KIT expression
DNMT3A deletion
Chr inv(16)t(16;16) + KIT mutation
KIT D816H
RUNX1 mutation
EZH2 mutation
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation
KMT2A rearrangement
BCR-ABL1 fusion
TET2 mutation
BCR-ABL1 mutation
KMT2A-PTD
TET2 L1231P
TET2 E227
KMT2A expression
Chr del(5q) + Chr amplification(21)(q22) RUNX1
KMT2A mutation
CEBPA mutation
ASXL1 mutation
SF3B1 mutation
DNMT3A mutation + NPM1 mutation
FLT3-ITD mutation + IDH1 mutation
NPM1 mutation + DNMT3A mutation
JAK2 mutation
JAK2 V617F
CD19 expression + Chr t(8;21)
RARA overexpression
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation
RUNX1-RUNX1T1 fusion + KIT D816
FLT3 mutation + IDH1 mutation
BCL2 mutation
CD19 positive + Chr t(8;21)
RARA positive
BCL2 expression
BCL2 overexpression
JAK2 amplification
DNMT3A mutation + IDH mutation
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
CD74 expression
MYC amplification
PTPN11 mutation
SETD2 mutation + RUNX1 mutation
BRAF mutation + TET2 mutation
KMT2A rearrangement + NPM1 mutation
DDX41 mutation
CD123 positive + FLT3-ITD mutation
LILRB4 overexpression
P2RY8-CRLF2 fusion
NPM1 mutation + SRSF2 mutation
NUP98-PRRX1 fusion
SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation
BCOR mutation
CSF3R mutation
BCL2/MCL1 ratio elevation
CEBPZ rearrangement + FLT3-TKD mutation
TNFRSF8 expression
FLT3-ITD mutation + RIPK1 expression
BCL2/BCL2L1 ratio elevation
ABL1 expression
MAGEE1 expression
IKZF2 expression
BCR expression
SPINK2 overexpression
ARHGAP20 expression
ETS1 expression
FLT3-ITD mutation + SKI overexpression
STAG2 mutation
NUP98-NSD1 fusion + FLT3-ITD mutation
SH3D19 expression
SETBP1 expression
HLF overexpression + FLT3-ITD mutation
MEIS1 overexpression
CLEC7A overexpression
GLI3 expression
PTPN11 mutations + MCL1 overexpression
BCL2A1 expression
KRAS mutation + BCL2A1 overexpression
CD14 overexpression
HOXA9 overexpression
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation
STAT5b-RARA fusion
HOXA9 overexpression + MEIS1 overexpression
IDH2 mutation + SRSF2 mutation
FLT3-ITD mutation + IDH2 mutation
WSB1 expression
BNIP3L elevation
LDHA elevation
HIF1A overexpression
U2AF1 mutation
NPM1 mutation + DNMT3A mutation + KMT2D mutation
AXL elevation
ANG elevation
SLFN11 expression
KAT6A-CREBBP fusion + FLT3-TKD mutation
MTHFR underexpression
SPI1 deletion
ETV6-NTRK3 fusion
GNG4 expression
PD-L1 underexpression
WT1 underexpression
PHF6 mutation
RET expression
NAV3 expression
GAS1 expression
TFRC expression
RNF217-AS1 expression
FLT3 A848P + MLL-MLLT3 fusion
FLT3-ITD mutation + MLL fusion + TP53 mutation
FLT3 mutation + PTPN11 mutation
FLT3 mutation + NRAS mutation + PTPN11 mutation
IDH1 R132H + PTEN C78T
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
IL3RA positive
IDH2 mutation + NPM1 mutation
Chr inv(16)(p13;q22)/ CBFB-MYH11 fusion
FIP1L1-PDGFRA rearrangement
IDH1 mutation + TP53 mutation
IDH2 mutation + TP53 mutation
NUP98 rearrangement
KRAS wild-type
MECOM rearrangement
PTGS2 expression
TNFRSF10D expression
NUP98-HOXD11 fusion + Chr t(2;11)(q31;p15)
NUP98-RARG fusion
WT1 overexpression
IDH2 R140Q + NPM1 mutation
WT1 mutation
KRAS mutation
MYC translocation
KRAS G12A
KRAS mutation + U2AF1 mutation
FIP1L1-PDGFRA fusion
PD-L1 overexpression
MYC expression
MYC overexpression
CD14 expression
FLT3 wild-type + TP53 mutation
Chr inv(3)t(3;3) + MECOM overexpression
SLFN11 underexpression
CBFB-MYH11 fusion
MLL rearrangement
MLL rearrangement
Chr del(5q)
Chr del(17p)
Chr t(5;7;7)(q33.2;q32;q11.2)
Chr t(14;21)(q22;q22)
RAS mutation
Chr t(15;17)
ARNT expression
RASGRP1 overexpression
BAX expression
GATA1 overexpression
Chr t(8;21)(q22;q22)
NF1 deletion
DCK exon 4 mutation
DCK exon 6 mutation
NFKB1 overexpression
PIM2 overexpression
Chr del(7q)
IKZF1 deletion + VPREB1 deletion
IKZF1 deletion + CDKN2B deletion
IKZF1 deletion + CDKN2A deletion
MCL1 S159A
NRAS mutation
ZBTB16-RARA fusion
IL1A elevation
NPM-RARA fusion
BRCA1 expression
BRCA2 expression
CCL2 overexpression
PDE3A overexpression
GATA2 mutation
CXCL10 elevation
NRAS mutation + U2AF1 mutation
MYC overexpression + IDH2 mutation
CD276 expression
MYC overexpression + IDH1 mutation
CD34 positive
CD34 positive + MN1 overexpression + MCL1 elevation
CD34 positive + BMI1 overexpression + MAP2K1 elevation
CBFA2T3 - GLIS2 fusion
HK2 overexpression
CBL mutation
MCL1 expression
MCL1 overexpression
ANXA1 overexpression
CD33 expression + CD7 expression
DDB2 rs830083
KDM1A overexpression
CCL11 overexpression
TGFA overexpression
CCL22 underexpression
HOXA11 overexpression
BST1 positive
MYC-IGH fusion
NUP98-KDM5A fusion
NUP98-NSD1 fusion
FLT3 mutation + NRAS mutation
IGH translocation
CD70 expression
MLL mutation
FASN-L
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation
DNMT3A mutation + ASXL1 mutation + NRAS mutation
DNMT3A mutation + NRAS mutation
HMGA1 deletion+ JAK2 V617F
GFI1 36N
MLL-PTD
IDH2 mutation + NRAS mutation
DNMT3A mutation + ASXL1 mutation
ASXL1 mutation + NRAS mutation
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation
BRAF mutation
FLT3-ITD mutation + ASXL1 mutation
FOLR1 expression
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation
miR-155 deletion + FLT3-ITD mutation
CCND3 Q276* + CCND3 S264R
TPBG expression
PD-L2 overexpression
EPOR amplification
ITGAM expression
FCGR1A positive
MAFB expression
LRP1 expression
KDM6A mutation
IGF2R overexpression
HLA-A*02:01
CTSA overexpression
ATP6AP2 overexpression
KMT2A rearrangement + RAS mutation
MERTK expression
SIRT3 expression
NFE2L2 overexpression
Chr t(3;5)(q25;q35)
SLC1A5 underexpression
SLC1A5 overexpression
MLL fusion
PTPRC positive + KMT2A rearrangement
CCND3 T283A
MLL-AF4 fusion
Chr t(8;21)(q22;q22) + RUNX1-RUNX1T1 fusion + KIT exon 17 mutation + CSF3R mutation
PTPRC positive
CRLF2 rearrangement
JAK2 mutation + CRLF2 rearrangement
NPM1 mutation + NRAS mutation
MLL translocation
NRAS G12D
Chr t(15;17)/PML-RARA fusion
FGFR1OP2-FGFR1 fusion
LYN overexpression + FLT3-ITD mutation
IKZF1 deletion
HCK overexpression + FLT3-ITD mutation
CSK overexpression + FLT3-ITD mutation
EPHB2 overexpression + FLT3-ITD mutation
Chr rearrangement(11)(q23)
TNFRSF4 expression
HAVCR2 expression
MSLN overexpression
BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression
AR underexpression + IL1R1 underexpression + CCND1 overexpression
FLT3-ITD mutation + NRAS mutation + GATA2 mutation
GADD45A overexpression + BCL2L10 overexpression + PMAIP1 overexpression
BCL2L1 overexpression
INPP4B overexpression